Patents by Inventor Mark Gelfand

Mark Gelfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9687636
    Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: June 27, 2017
    Assignee: BackBeat Medical, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 9675413
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 13, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Patent number: 9636174
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 2, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9629679
    Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 25, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
  • Publication number: 20170080214
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: September 19, 2016
    Publication date: March 23, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20170080230
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Publication number: 20170065336
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 9, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20170065337
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Application
    Filed: August 8, 2016
    Publication date: March 9, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Publication number: 20170056087
    Abstract: Neuromodulation cryotherapeutic devices and associated systems and methods are disclosed herein. A cryotherapeutic device configured in accordance with a particular embodiment of the present technology can include an elongated shaft having distal portion and a supply lumen along at least a portion of the shaft. The shaft can be configured to locate the distal portion intravascularly at a treatment site proximate a renal artery or renal ostium. The supply lumen can be configured to receive a liquid refrigerant. The cryotherapeutic device can further include a cooling assembly at the distal portion of the shaft. The cooling assembly can include an applicator in fluid communication with the supply lumen and configured to deliver cryotherapeutic cooling to nerves proximate the target site when the cooling assembly is in a deployed state.
    Type: Application
    Filed: August 5, 2016
    Publication date: March 2, 2017
    Inventors: Naomi Buckley, Benjamin J. Clark, Michael Cummins, Danny Donovan, Mark Gelfand, Luke Hughes, Brian Kelly, Gary Kelly, Grace Kelly, John Kelly, Mark S. Leung, Gwenda McMullin, Barry Mullins, Karun D. Naga, Stephen Nash, Eric Ryba, Fiachra Sweeney, Vicenzo Tilotta, Roman Turovskiy, Lana Woolley, Denise Zarins, Michael Turovskiy
  • Publication number: 20170049554
    Abstract: A method and device to improve lung function in a patient having restricted ventilation. The device may include an implantable airway bypass device that relieves trapped air. The method may include a treatment procedure that minimizes irritation of tissue to control healing processes.
    Type: Application
    Filed: April 30, 2015
    Publication date: February 23, 2017
    Applicant: Soffio Medical Inc.
    Inventors: Jianmin LI, George BOURNE, Mark GELFAND, Howard LEVIN, Michael BARENBOYM, Ary CHERNOMORSKY, Benjamin David BELL, Gerhard Andrew FOELSCHE, Mark LEUNG
  • Publication number: 20170007319
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: March 14, 2016
    Publication date: January 12, 2017
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20170007325
    Abstract: Microwave catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a microwave transmission element to a renal artery via an intravascular path. Renal neuromodulation may be achieved via dielectric heating in the presence of microwave irradiation that modulates neural fibers that contribute to renal function or alters vascular structures that feed or perfuse the neural fibers.
    Type: Application
    Filed: September 9, 2016
    Publication date: January 12, 2017
    Inventors: Karun D. Naga, Roman Turovskiy, Denise Zarins, Mark Gelfand, Arye Rosen
  • Publication number: 20170007320
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: March 17, 2016
    Publication date: January 12, 2017
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20160374710
    Abstract: Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation. The methods may be performed using an ultrasound ablation catheter. The methods may also include imaging using at least one ultrasound imaging catheter.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Inventors: Yegor D. SINELNIKOV, Zoar Jacob ENGELMAN, Mark GELFAND, Martin M. GRASSE, Timothy A. KOSS, Michael Brick MARKHAM, Kenneth M. MARTIN, Veijo T. SUORSA, Miriam H. TAIMISTO, Xian WEI, Brice Arnault DE LA MENARDIERE, Clayton Miles BALDWIN, Jason MILLER
  • Patent number: 9526833
    Abstract: A patient hydration system including an infusion device for administering hydration fluid to a patient, and a hydration fluid measurement device responsive to a source of hydration fluid, a patient urine output measurement device. A controller is responsive to the hydration fluid measurement device and the patient urine output measurement device. The controller operates the infusion device, in response to the patient urine output measurement device and the hydration fluid measurement device, to hydrate the patient based on the patient's urine output. The controller also monitors the operation history of the infusion device thereby providing redundancy in the measurement of the amount of hydration fluid administered to the patient.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 27, 2016
    Assignee: PLC Medical Systems, Inc.
    Inventors: Mark Gelfand, Howard R. Levin
  • Publication number: 20160338753
    Abstract: Methods and cryogenic devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation. Some methods include advancing a cryo-ablation catheter into a patient's vasculature and ablating tissue within a carotid septum.
    Type: Application
    Filed: August 2, 2016
    Publication date: November 24, 2016
    Inventors: Eric RYBA, Mark GELFAND
  • Publication number: 20160339244
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.
    Type: Application
    Filed: August 2, 2016
    Publication date: November 24, 2016
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20160338724
    Abstract: Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.
    Type: Application
    Filed: March 14, 2016
    Publication date: November 24, 2016
    Inventors: Yegor D. SINELNIKOV, Zoar Jacob ENGELMAN, Mark GELFAND, Martin M. GRASSE, Timothy A. KOSS, Michael Brick MARKHAM, Kenneth M. MARTIN, Veijo T. SUORSA, Miriam H. TAIMISTO, Xian WEI
  • Publication number: 20160331446
    Abstract: Described herein are methods and endovascular catheters, configured for delivery to a carotid artery from a subclavian artery approach, for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.
    Type: Application
    Filed: January 5, 2015
    Publication date: November 17, 2016
    Inventors: Kenneth M. MARTIN, Mark GELFAND, Michael Brick MARKHAM
  • Publication number: 20160325098
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 10, 2016
    Inventors: Howard R. Levin, Mark Gelfand